<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868514</url>
  </required_header>
  <id_info>
    <org_study_id>P050001 TiLOOP® Bra Pocket</org_study_id>
    <nct_id>NCT03868514</nct_id>
  </id_info>
  <brief_title>Post Market Clinical Follow Up to &quot;Patient Reported Outcome&quot; Using a Titanised Polypropylene Mesh (TiLOOP® Bra Pocket)</brief_title>
  <acronym>PRO-Pocket</acronym>
  <official_title>&quot;PRO-Pocket&quot; - International Prospective Multicenter Post Market Clinical Follow Up to &quot;Patient Reported Outcome&quot; in Primary or Secondary Breast Reconstruction After Mastectomy Using a Titanised Polypropylene Mesh (TiLOOP® Bra Pocket)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pfm medical ag</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pfm medical ag</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;PRO-Pocket&quot; - International prospective multicentre Post Market Clinical Follow Up to
      &quot;Patient reported outcome&quot; in primary or secondary breast reconstruction after mastectomy
      using a titanised polypropylene mesh (TiLOOP® Bra Pocket)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This international, multicentre, non-randomised, observational clinical device investigation
      will be performed to obtain post market information on TiLOOP® Bra Pocket surgical meshes for
      a period of up to two years. In particular, on patient reported satisfaction (BreastQTM),
      cosmetic outcome and the rate of complications.

      The objective of the clinical Investigation is to establish the efficacy and safety of the
      TiLOOP® Bra Pocket.

      The Investigation will be performed in ten clinical centres in Germany and Austria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life - Patient reported outcome</measure>
    <time_frame>12 months after study treatment</time_frame>
    <description>The primary endpoint is defined as the change of the four BreastQ domain scores before study treatment compared to twelve months after study treatment. The BreastQ questionnaire yields a domain score in the range from zero to 100. Wheras a score of 100 is the best score. The study hypothesis is that the patient's QoL after the study intervention treatment is not worse than the QoL prior to the intervention study treatment . The following four domains are relavant: Satisfaction with breasts, Psychosocial well-being, Physical well-being:chest and Sexual well-being.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Patient reported outcome</measure>
    <time_frame>6 and 24 months after study treatment</time_frame>
    <description>The change of the four BreastQ domain scores before study treatment compared to six months and 24 months after study treamtment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>6, 12 and 24 months after study treatment</time_frame>
    <description>The number and rate of occurrence of adverse events is reported as a secondary endpoint along with a tabulation of the types of adverse events (6, 12 and 24 months after study treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>6, 12 and 24 months after study treatment</time_frame>
    <description>The cosmetic outcome is assessed based on photographs 6, 12 and 24 months after study treatment by descriptive statistics (an independent expert, the physician in charge and the patient assess the cosmetic outcome).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Reconstruction After Mastectomy</condition>
  <arm_group>
    <arm_group_label>TiLOOP Bra Pocket</arm_group_label>
    <description>Medical Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TiLOOP® Bra Pocket</intervention_name>
    <description>Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket</description>
    <arm_group_label>TiLOOP Bra Pocket</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with indicated implant based breast reconstruction after mastectomy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age [≥ 18]

        Indications of breast reconstruction: histologically confirmed breast cancer, precancerous
        lesions (DCIS, LCIS), mutation carrier with increased breast cancer risk, strong family
        history (lifetime risk &gt; 15%)

        The patient is capable to realise the nature, aims and possible consequences of the
        clinical trial (MPG §20.2.1)

        Patient information has been provided and all written consents of the patient are available

        Exclusion Criteria:

        Metastatic breast cancer

        Patient with known contraindications against mesh-assisted or plastic-reconstructive breast
        surgery according to the instruction for use

        Patient is kept in an institution under judicial or official orders (MPG §20.3)

        Participate in another operative clinical trial, if it relates to the area of
        reconstructive breast surgery and/or influences the primary endpoint of the clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katja Klein</last_name>
    <phone>0049 22369641</phone>
    <phone_ext>250</phone_ext>
    <email>katja.klein@pfmmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde, Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daphne Gschwantler-Kaulich, Assoc. Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Daphne Geschwantler-Kaulich, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Gerber-Schäfer, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Claudia Gerber-Schäfer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ankel, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christine Ankel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andree Faridi, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Andree Faridi, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte; Evang. Huyssens-Stiftung</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherko Kümmel, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sherko Kümmel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Thill, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marc Thill, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Heil, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jörg Heil, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>Munich</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Paepke, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Paepke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Visnja Fink, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Visnja Fink, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GRN Klinik Weinheim</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lelia Bauer, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Lelia Bauer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast reconstruction</keyword>
  <keyword>surgical mesh</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

